Overall index of data tables

The following overall index lists the tables in the bulletin, the associated graphics and the tables in the annex to the bulletin.

Bulletin tables

• Table GPSurvey-1. Lifetime prevalence of drug use among all adults (15-64 years old) in nationwide surveys among the general population
• Table GPSurvey-1 Part (i) Lifetime prevalence all adults
• Table GPSurvey-1 Part (ii) Survey methods
• Table GPSurvey-1 Part (iii) Sources
• Table GPSurvey-2. Lifetime prevalence of drug use among young adults (15-34 years old) in nationwide surveys among the general population
• Table GPSurvey-3. Last year prevalence of drug use among all adults (15-64 years old) in nationwide surveys among the general population
• Table GPSurvey-4. Last year prevalence of drug use among young adults (15-34 years old) in nationwide surveys among the general population
• Table GPSurvey-5. Last month prevalence of drug use among all adults (15-64 years old) in nationwide surveys among the general population
• Table GPSurvey-6. Last month prevalence of drug use among young adults (15-34 years old) in nationwide surveys among the general population
• Table GPSurvey-7. Last 30 days prevalence and frequency of use of cannabis amongst all adults and young adults, according to population surveys
• Table GPSurvey-7 Part(i) Last 30 days prevalence (percentage)
• Table GPSurvey-7 Part(ii) Frequency of use among all users in last 30 days (percentage)
• Table Prevalence-1. School surveys: Lifetime prevalence of psychoactive substance use among 15-16 years old students
• Table Prevalence-2. School surveys: prevalence of cannabis use among students aged 15-16 years
• Table Prevalence-2 Part (i) Lifetime prevalence (LTP), Last year prevalence (LYP), and Last month prevalence (LMP)
• Table Prevalence-2 Part (ii) Use patterns
• Table Prevalence-3. Numbers of problem drug users, estimated by various methods, 1995-2002
• Table Prevalence-3 Part (i) Numbers of problem drug users
• Table Prevalence-3 Part (ii) Numbers of problem drug users assumed to be injecting
• Table Prevalence-4. Prevalence of problem drug use (rate per 1000 aged 15-64) estimated by various methods, from 1995 to 2002
• Table Prevalence-4 Part (i) Prevalence of problem drug use
• Table Prevalence-4 Part (ii) Prevalence of problem drug use assumed to be injecting use
• Table Prevalence-0. School surveys: Sources
• Table Prison-1. Prevalence of lifetime use of various drugs among prisoners (estimated percentage)
• Table Prison-2. Prevalence of lifetime injecting drug use among prisoners (estimated percentage)
• Table Prison-3. Prevalence of drug use within prison among prisoners (estimated percentage)
• Table Prison-4. Prevalence of injecting drug use within prison among prisoners (estimated percentage)
• Annex Table Prison-5 Overall Annex Table of studies of drug use in prisons
• Table Prison-0. Prevalence of drug use among prisoners - Sources and Bibligraphic References
• Annex Table Prison-5 Overall Annex Table of studies of drug use in prisons
• Table IDisease-1. Prevalence of HIV infection among injecting drug users - summary table
• Table IDisease-2. Prevalence of HCV infection among injecting drug users - summary table
• Table IDisease-3. Prevalence of markers for HBV infection among injecting drug users - summary table
• Table IDisease-4. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2003, (a) cases per million population and (b) number of cases
• Table IDisease-5. Notified cases of hepatitis C infection among injecting drug users: number of IDUs and percentage of IDUs amongst all cases with known risk factor
• Table IDisease-5 Part (i) Notifications IDUs with hepatitis C
• Table IDisease-5 Part (ii) Notes and comments
• Table IDisease-6. Notified cases of hepatitis B infection among injecting drug users: number of IDUs and percentage of IDUs amongst all cases with known risk factor
• Table IDisease-6 Part (i) Notifications of IDUs with hepatitis B
• Table IDisease-6 Part (ii) Notes and comments
• Table IDisease-7. Incidence of hepatitis C virus antibody among injecting drug users
• Annex Table IDisease-8 Prevalence of HIV (%) among IDUs of all ages
• Annex Table IDisease-9 Prevalence of HIV (%) among IDUs under 25 years old
• Annex Table IDisease-10 Prevalence of HIV (%) among new IDUs
• Annex Table IDisease-11 Prevalence of HCV (%) among IDUs of all ages
• Annex Table IDisease-12 Prevalence of HCV (%) among IDUs under 25 years old
• Annex Table IDisease-13 Prevalence of HCV (%) among new IDUs
• Annex Table IDisease-14 Prevalence of current Hepatitis B (% with HbsAg) among IDUs of all ages
• Annex Table IDisease-15 Prevalence of antibodies for HBV (%) among IDUs of all ages
• Table IDisease-0. Infectious Diseases - Bibliographic References
• Table IDisease-0 Part (i) Infectious Diseases - Prevalence
• Table IDisease-0 Part (ii) Infectious Diseases - Notifications
• Table DRDeath-1. Summary of characteristics of the deceased in drug-related deaths
• Table DRDeath-1 Part (i) 2002 or last year with available information
• Table DRDeath-1 Part (ii) 1990 or closest year with available information
• Table DRDeath-2. Number of acute drug-related deaths recorded in EU member states (15 members up to 2004) according to national definitions, 1985-2002
• Table DRDeath-2 Part (i) Total drug-related deaths 1985 onwards
• Table DRDeath-2 Part (ii) Male drug-related deaths 1990 to 2002
• Table DRDeath-2 Part (iii) Female drug-related deaths 1990 to 2002
• Table DRDeath-2 Part (iv) Sources
• Table DRDeath-3. Number of acute drug-related deaths recorded in the new EU and other countries according to national definitions, 1990-2002
• Table DRDeath-3 Part (i) Total drug-related deaths
• Table DRDeath-3 Part (ii) Male and female drug-related deaths
• Table DRCrime-1. Number of reports for drug law offences, 1985-2002
• Part (i) 1995 to 2002
• Part (ii) 1985 onwards
• Table DRCrime-2. Offence type most involved in the reports for drug law offences in 2002/2001 
• Table DRCrime-3. Drug types involved in reports for drug law offences: percentage of all reports for drug law offences in 2002/2001 
• Table DRCrime-4. Percentage of total drug law offences that are related to drug use or possession for use, 1996-2002
• Table DRCrime-5. Cannabis-related offences: percentage among total drug law offences, 1996-2002
• Table DRCrime-6. Heroin-related offences: percentage among total drug law offences, 1996-2002
• Table DRCrime-7. Cocaine-related offences: percentage among total drug law offences, 1996-2002
• Table TDI-1. Total numbers of new clients at drug treatment centres, 1996 to 2002
• Table TDI-2. Number of cases covered by treatment demand indicator reports, by country and by data source in 2002: New clients and All clients
• Table TDI-3. Gender distribution and mean age among new and all clients at out-patient treatment centres in 2002
• Table TDI-4. Age distribution (percent) among all clients in treatment by main drug, for those countries supplying data for 2002
• Table TDI-5. Distribution of age at first use of main drug by all clients in treatment, from all sources, for those countries supplying data for 2002
• Table TDI-6. Distribution of educational level (percentage) among all clients attending out-patient treatment in 2002
• Table TDI-7. Distribution of labour status (percentage) amongst all clients attending out-patient treatment in 2002
• Table TDI-8. Frequency of cannabis use (in percentages) in the past month amongst all cannabis (primary drug) patients attending outpatient treatment in 2002
• Table TDI-9. Secondary drug used: percentage among all cannabis (primary drug) clients attending out-patient treatment in 2002
• Table TDI-10. Characteristics of all clients treated for drug problems: demographics and primary drug at treatment in 2002 or most recent year available
• Table TDI-10 Part (i) Demographics and injecting status
• Table TDI-10 Part (ii) main drug (percentage) and of those the percent injecting it (italics)
• Table TDI-10 Part (iii) Sources
• Table TDI-11. Characteristics of new clients treated for drug problems: demographics and main drug at treatment in 2002 or most recent year available
• Table TDI-11 Part (i) Demographics and injecting status
• Table TDI-11 Part (ii) Main drug (percentage) and of those the percent injecting it (italics)
• Table TDI-12. Characteristics of all women treated for drug problems in 2002 or most recent year available
• Table TDI-12 Part (i) Demographics and injecting status
• Table TDI-12 Part (ii) Distribution of primary drug (percentage)
• Table TDI-13. Characteristics of all men treated for drug problems in 2002 or most recent year available
• Table TDI-13 Part (i) Demographics and injecting status
• Table TDI-13 Part (ii) Distribution of primary drug (percentage)
• Table Markets-1. Number of cannabis seizures, 1985-2002
• Table Markets-1 Part (i) 1994 to 2002
• Table Markets-1 Part (ii) 1985 to 2002
• Table Markets-2. Quantities of cannabis seized, 1985-2002 (kgs)
• Table Markets-2 Part (i) 1994 to 2002
• Table Markets-2 Part (ii) 1985 to 2002
• Table Markets-3. Number of heroin seizures, 1985-2002
• Table Markets-3 Part (i) 1994 to 2002
• Table Markets-3 Part (ii) 1985 to 2002
• Table Markets-4. Quantities of heroin seized (kgs), 1985-2002
• Table Markets-4 Part (i) 1994 to 2002
• Table Markets-4 Part (ii) 1985 to 2002
• Table Markets-5. Number of cocaine seizures, 1985-2002
• Table Markets-5 Part (i) 1994 to 2002
• Table Markets-5 Part (ii) 1985 to 2002
• Table Markets-6. Quantities of cocaine seized, 1985-2002 (kgs)
• Table Markets-6 Part (i) 1994 to 2002
• Table Markets-6 Part (ii) 1985 to 2002
• Table Markets-7. Number of amphetamines seizures, 1985-2002
• Table Markets-7 Part (i) 1994 to 2002
• Table Markets-7 Part (ii) 1985 to 2002
• Table Markets-8. Quantities of amphetamines seized, 1985-2002 (kgs)
• Table Markets-8 Part (i) 1994 to 2002
• Table Markets-8 Part (ii) 1985 to 2002
• Table Markets-9. Number of ecstasy seizures, 1987-2002
• Table Markets-9 Part (i) 1994 to 2002
• Table Markets-9 Part (ii) 1987 to 2002
• Table Markets-10. Quantities of ecstasy seized, 1985-2002 (tablets)
• Table Markets-10 Part (i) 1994 to 2002
• Table Markets-10 Part (ii) 1985 to 2002
• Table Markets-11. Number of LSD seizures, 1985-2002
• Table Markets-11 Part (i) 1994 to 2002
• Table Markets-11 Part (ii) 1985 to 2002
• Table Markets-12. Quantities of LSD seized, 1985-2002 (doses)
• Table Markets-12 Part (i) 1994 to 2002
• Table Markets-12 Part (ii) 1985 to 2002
• Table Markets-13. Drug seizures in 2002: numbers of seizures and total quantity
• Table Markets-14. Price of different illicit drugs at retail level, 2002
• Table Markets-14 Part (i) Minimum, maximum and average price in Euros
• Table Markets-14 Part (ii) Sources of information
• Table Markets-15. Average potency of cannabis resin at retail level, measured as percentage THC content from 1998 to 2002
• Table Markets-16. Average potency of herbal cannabis at retail level, measured as percentage THC content from 1998 to 2002

Associated graphics

• Evolution of cannabis use (last year prevalence) among young people in some EU countries measured by population surveys
  [Figure5OL]. See also Tables GPSurvey-4 and Prevalence-2 Part (i)
• Evolution of recent use (past year) of amphetamines and ecstasy among young adults (15-34 years old) in the United Kingdom
  [Figure6OL]. See also Table GPSurvey-4
• Relative frequency of cannabis (last year prevalence) use among 15-year-old school students who used during past year
  [Figure4OL]. See also Table Prevalence-2 Part (ii)

• The proportion of people over 35 years among victims of acute drug-related deaths in the EU countries in 1990 and in 2001/2
  [Figure10OL]. See also Tables DRDeath-1 Part (i) and Part (ii)
• Long-term EU trend in acute deaths directly related to drug use (1985-2001)
  [Figure11OL]. See also Table DRDeath-2 Part (i)
• Trends in acute drug-related deaths in the different EU countries (1985-2002)
  [Figure12OL]. See also Table DRDeath-2 Part (i)

• New clients in treatment by year in some EU countries (1996-2002)
  [Figure17OL]. See also Table TDI-1
• Trends in current injecting drug use amongst heroin users in treatment
  [Figure9OL]. See also Tables TDI-10 Part (i) and TDI-11 Part (i)
• Distribution of age at first use of main drug by all clients in outpatient treatment in 2002 (in total for those countries supplying data)
  [Figure18OL]. See also Table TDI-5
• Distribution of educational level amongst all outpatient treatment clients, by country, in 2002
  [Figure19OL]. See also Table TDI-6

Annex tables

• Annex Table Prevalence-5. Estimates of prevalence from local studies of problem drug use among 15-64 year-olds

• Annex Table Prison-5 Overall Annex Table of studies of drug use in prisons

• Annex Table IDisease-8 Prevalence of HIV (%) among IDUs of all ages
• Annex Table IDisease-9 Prevalence of HIV (%) among IDUs under 25 years old
• Annex Table IDisease-10 Prevalence of HIV (%) among new IDUs
• Annex Table IDisease-11 Prevalence of HCV (%) among IDUs of all ages
• Annex Table IDisease-12 Prevalence of HCV (%) among IDUs under 25 years old
• Annex Table IDisease-13 Prevalence of HCV (%) among new IDUs
• Annex Table IDisease-14 Prevalence of current Hepatitis B (% with HbsAg) among IDUs of all ages
• Annex Table IDisease-15 Prevalence of antibodies for HBV (%) among IDUs of all ages